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The objective of the article was to describe a female patient with rheumatoid arthritis (RA) 
and secondary Sjögren’s syndrome (SS) who developed a renal oncocytoma and was cured 
by percutaneous cryoablation therapy. A 72-year-old female patient with a long-term history 
of polyarthritis involving her hands, shoulders, knees, and ankles associated with morning 
stiffness and rheumatoid factor of 107 U/mL (nr: <29 U/mL) and anti-CCP of 121 U/mL (nr: 
<5 U/mL). A diagnosis of RA was determined 10 years ago, and prednisone with methotrexate 
were initiated, later changed for leflunomide 20mg/day. In 2014 a diagnosis of secondary SS 
was determined. In April 2014, during a routine abdominal ultrasound, a tumor was found in 
her left kidney. A magnetic resonance imaging confirmed a solid nodule with hypervascular-
ization on the left kidney. She was submitted to a percutaneous cryoablation procedure with-
out any intercurrence, and it had success. The histopathological analysis demonstrated a renal 
oncocytoma limited to the left kidney. No chemotherapy or radiotherapy was needed. After 
surgery, a flare of RA was noted and was resistant to methotrexate and sulfasalazine. Ritux-
imab was then started, and she had an excellent progressive response. Minor thyroid changes 
were registered by ultrasound monitoring and signs of hyperparathyroidism manifested. This 
observation illustrates the first ever described case of a patient with RA and secondary SS who 
developed several years after the RA onset, a renal oncocytoma, and was successfully treated 
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with cryoablation therapy. The possible links between oncocytic cell metaplasia/neoplasia and 
autoimmunity are discussed.
Keywords: rheumatoid arthritis, oncocytoma, tumor, neoplasia, metaplasia, dysplasia, autoim-
munity, cancer, immunosuppressive drugs, Sjögren’s syndrome, Hürthle — Askanazy cells, 
Hashimoto’s thyroiditis. 
Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune disease, which involves synovial 
joints. It may lead to articular destruction if not treated and in most cases is characteris-
tic for the presence of autoantibodies towards native nucleohistones/Fc-fragments of im-
munoglobulins (known as rheumatoid factor, RF) and/or anti-cyclic citrullinated protein 
(anti-CCP) autoantibodies [1].
RA is associated with an increased incidence of some neoplastic disorders, mainly 
lymphoid leukemia, lymphoma and also lung cancer. The pathogenesis of this augmented 
oncological risk is multifactorial and includes shared risk factors (like, smoking for both 
RA and lung cancer), the presence of chronic inflammation and somatic hypermutation 
of lymphoid clones involved in autoimmune process, as well as the use of immunosup-
pressive drugs and biologicals commonly applied in RA [2]. Several other cancers were 
described in RA, including colorectal, prostate and breast ones, as well as melanoma [3]. 
But for many cancers no relation to RA was revealed, moreover, the incidence of colorectal 
cancers in various cohorts of RA patients was even decreased [4–7]. However, to the best 
of our knowledge, so far no RA case associated with renal oncocytoma was described. 
This article aims to report the case of a patient with RA and secondary Sjögren’s 
syndrome (SS) who developed a renal oncocytoma successfully cured by a percutaneous 
cryoablation procedure. 
Case report
A  72-year-old female patient with arterial hypertension, dyslipidemia, osteopenia 
and age-related macular degeneration in anamnesis, had hysterectomy due to leiomyoma 
20 years ago. She had a long-term history of polyarthritis of her hands, shoulders, knees, 
and ankles associated with morning stiffness. A diagnosis of RA was determined 10 years 
ago, and courses of prednisone and methotrexate were initiated, later changed for leflu-
nomide 20mg/day. She came to private clinic in August 2012 with polyarthritis of wrists, 
left ankle, knees, and second and third metacarpophalangeal joints bilaterally associated 
with morning stiffness with duration of 5 minutes. Laboratory tests revealed a normal 
cell blood count, erythrocyte sedimentation rate (ESR) of 90  mm/1st hour, C-reactive 
protein of 1.8 mg/L (normal range: < 0.1 mg/dL), normal blood biochemical parameters 
(AST 25 U/L and ALT 15 U/L, gamma-glutamyl transferase 26 U/L), RF of 107 IU/mL 
(nr: <29  IU/mL) and anti-CCP of 121  U/mL (nr: <5  U/mL). Methotrexate was added 
to leflunomide in a 15 mg/week dose combined with folic acid 5 mg/week and vitamin 
D3 50,000 IU/week. After one month, a marked improvement was observed, no arthritis 
was noted, and ESR was reduced to 22 mm/1st hour and CRP to 0.1 mg/L with normal 
blood level of liver enzymes. In October 2013, she experienced diffuse moderate alopecia, 
and leflunomide was excluded, improving hair problems. In March 2014, she reported xe-
Вестник СПбГУ. Медицина. 2021. Т. 16. Вып. 2 79
rostomia and xerophthalmia, a Schirmer test showed 8 mm in the left eye and 6 mm in the 
right eye in 5 min, Bengal rose test was positive, salivary glands scintigraphy was positive, 
and a diagnosis of secondary Sjögren’s syndrome (SS) was determined. In April 2014, dur-
ing a routine abdominal ultrasound, one tumor was found in her left kidney. A magnetic 
resonance imaging confirmed a solid nodule with hypervascularization on the left kidney. 
She was submitted to a percutaneous cryoablation procedure without any intercurrence, 
and it had success. The histopathological analysis demonstrated a renal oncocytoma lim-
ited to the left kidney. No chemotherapy or radiotherapy was needed. After surgery, a flare 
of RA was noted, and methotrexate was increased to 25mg/week with bad disease control. 
Sulfasalazine 2g was added, but no response was observed. Anti-CCP was 390 U/mL, RF 
256 IU/mL, CRP 6.65 mg/L. She was negative for both anti-thyroglobulin and anti-TPO 
autoantibodies, and euthyroid, having TSH 0.44 (nr: 0.3–4.0 mU/L) and free T4 1.35 (nr: 
0.9–1.8  ng/dL). Although, her thyroid ultrasound revealed a reduced homogeneous 
gland with a gland volume of 3.6 cm3 (nr: 6–15 cm3) and a nodule of 0.4 × 0.4 × 0.4 cm 
on the right lobe. In April 2014, due to the recent history of tumor, SS associated, and 
refractory RA disease activity, rituximab 1 g was initiated and repeated after 15 days. A 
marked improvement of clinical RA disease activity was seen soon as one month later, 
and methotrexate was tapered from 20 mg/week to 7.5 mg/week in one year, with normal 
CRP 0.1 mg/L and ESR 6 mm/1st hour. Rituximab every six months was maintained, and 
methotrexate was suspended in this period. In September 2018, she presented hypercal-
cemia of 10.8 mg/dL (nr: 8.5–10.5 mg/dL), associated with a high parathyroid hormone 
of 136 pg/mL (nr: 10–65 pg/mL), a diagnosis of primary hyperparathyroidism was made, 
and endocrinologist addressed a conservative approach. 
Currently, two years later, the patient is asymptomatic, with RA under control, in-
flammatory markers are normal, and she is under rituximab every six months. The on-
cologists considered the tumor cured. 
Discussion
This article is the first description of oncocytoma in a patient with long-term RA and 
secondary SS.
RA has an increased risk of neoplasia, and the phenomenon is linked to several fac-
tors such as aging, drug use, chronic inflammation, and the presence of common risk 
factors such as smoking, infections, and others. The leading hypothesis is that it is oc-
curring an immunologic stimulus over time, which may increase the risk for malignant 
transformation of immune cells and reduce the suppressor function of lymphocytes, thus 
increasing the chance of lymphoma in these subjects [8].
An important risk factor for cancer developing in AR is the use of a TNF blockers. 
A  systematic review that included 123.031  cases indicated that RA individuals treated 
with these biological drugs are under increased risk of non-melanoma skin cancer (rela-
tive risk of 1.28; 95 % CI: 1.19–1.38, P = 0.056) [9]. Besides, the presence of autoantibodies 
seems to be also a risk factor for cancer in these RA patients. Confirming this hypothesis, 
a population-based case-control study linked to the Swedish nationwide cancer register 
showed an amplified risk for lung cancer in RA patients who were positive for rheumatoid 
and/or anti-CCP antibodies [10]. It is important to emphasize that our patient had both 
these autoantibodies positive.
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SS is an autoimmune disease characterized by sicca syndrome, autoantibodies to 
some ribonucleoproteins and high risk of neoplasia. In a metanalysis including 14 studies 
with a total of 14.523 patients, the authors found an increased overall cancer risk (pooled 
RR 1.53; 95 % CI 1.17 to 1.88), and risks of non-Hodgkin lymphoma (NHL) (pooled RR 
13.76; 95 % CI 8.53 to 18.99) and thyroid cancer [11]. However, no case of SS associated 
with renal oncocytoma was described so far.
Oncocytoma is tumor of low or no malignancy (carcinoma or adenoma) that has 
some challenges in its diagnosis. Usually, it is asymptomatic neoplasm, often discovered 
incidentally on cross-sectional imaging performed for other clinical indications [12], as it 
happened in our patient. 
Neoplastic process goes in multi-step sequence of somatic mutations, hence meta-
plasia and dysplasia of epitheliocytes in parenchymal organs may form oncocytoid foci, 
which precede oncocytomas [13]. Most often such oncocytoid dysplasia and oncocytomas 
are located in thyroid gland, but sometimes they may occur in kidney, parathyroid, liver or 
very seldom — in other organs [14; 15]. 
To our opinion, the comorbidity of oncocytoma with two autoimmune diseases in 
one individual, described in this case, is remarkable and non-coincidental.
The source of oncocytomas is a mutant clone of oncocytes, having a series of somatic 
mutations in mitochondrial DNA, altering the sub-units of oxidative phosphorylation 
complexes I and IV and ATPase–6 variant. The oxidative function in oncocytes is dimin-
ished, triggering a compensatory mechanism of increased mitochondrial biogenesis. Be-
cause of that, their granular, brightly eosinophilic, swollen cytoplasm is loaded with large 
dysplastic mitochondria [14]. 
Cells with oncocytic phenotype (possibly, of parafollicular origin) were first described 
in 1894 by Karl Hürthle (1860–1945) in canine thyroid gland [16], but four years later 
Max Askanazy (1865–1940) have shown the abundance of follicular oncocytes in human 
thyroid, in patients with Graves’–von Basedow disease [17]. Most probably, Askanazy’s 
cases were that of hashitoxicosis, because currently oncocytes or Hürthle — Askanazy 
cells (which are very rare in normal thyroid) are recognized as very typical for Hashi-
moto’s autoimmune thyroiditis and even prominent in this particular disorder, being 
one of its key pathomorphological sings, with majority of follicular thyrocytes showing 
this particular kind of metaplasia. That fact was noticed even in very first description of 
the Hashimoto’s disease and still considered to be important [18–20]. Oncocytes also are 
common elements of thyroid Hürthle cell tumors and present in some papillary and fol-
licular thyroid cancers [13]. Oncocytes, both in autoimmune thyroiditis and in oncocy-
tomas express plenty of thyroid peroxidase in abnormal mitochondrial location [21; 22]. 
They also express neuron-specific enolase, both enzymes targeted by autoimmune process 
in Hashimoto’s thyroiditis [23; 24]. Chaperonin HSP60, involved in pathogenesis of sev-
eral autoimmune diseases, is hyperexpressed by oncocytes, it presents on their plasma 
membrane and displays cross-reactivity both with thyroglobulin and thyroid peroxidase 
[25]. There is even a hypothesis that oxidative damage of these enzymes in dysfunctional 
mitochondria of oncocytes along with disorder of apoptosis control — may serve as pri-
mary lesion precipitating subsequent chronic autoimmune process [16]. Oncocytes in 
Hashimoto’s disease lack of the oxidative phosphorylation complex I, which is a target of 
T-killer cells apoptogenic attack, thus having a selective advantage and surviving under 
lymphocyte infiltration conditions [22]. 
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It has been shown that oncocytic metaplasia is the result of an increased immuno-
proteasome expression in oncocytes, which additionally linked this cell transformation to 
autoimmune and autoinflammatory processes [26].
In our patient, the oncocytoma was located in kidney. Renal oncocytoma, first de-
scribed in 1942  by L. Zippel [27] earlier also was related to immunopathological glo-
merular changes typical for autoimmune glomerular disease [28]. Oncocytomas are as 
a rule indolent and if non-diagnosed may grow up to giant weight (2–4.6 kilos) [29]. In 
our case because of relatively early occasional diagnosis a tumor however have reached 
just small size. 
Perhaps, in this case systemic autoimmune diseases and oncocytoma were mecha-
nistically linked. Indeed, we detected a very small thyroid gland in our patient though, 
in line with our hypothesis of a realtionshib among these diseases [19]. The subsequent 
manifestation of hyperparathyroidism in our patient could be related to parathyroid ad-
enoma, which also often may be oncocytic and even intrathyroid-located [30]. It raises a 
question of possible nature of a thyroid nodule revealed in our patient. For parathyroid 
tumors association between autoimmune lesion and oncocytic transformation of cells has 
been confirmed as well [31]. Alternative point of view on oncocytic transformation is 
based on the fact that prevalence of Hürthle — Askanazy cells in Hashimoto’s thyroiditis 
is progressively increasing with every decade of patient’s age, being non-typical for its pe-
diatric cases. Thus, their “hürthlization” can be regarded as survival reaction resulted from 
chronic immunopathological process and auto-aggression [32]. 
Hence, in our case of chronic systemic autoimmune diseases, like SS and RA, onco-
cytic metaplasia and dysplasia as a step towards oncocytoma also could be a result of epi-
thelial cell survival reaction for autoimmune aggression and/or facilitate autopresentation 
of the antigens abundant in oncocytes. 
Recently a case of renal oncocytoma positive, for alpha-enolase combined with au-
toimmune retinopathy and optic neuropathy was reported [33]. Oncocytomas have been 
repeatedly reported in association with various cases of autoimmune diseases, not only 
thyroid ones [34], but also bullous pemphigoid [35], and multiple sclerosis [36]. In auto-
immune diabetes mellitus type 1 there is a cross-reactivity between VP1 capsid protein of 
provoking enterovirus and mitochondrial proteins of oncocytoma cells [37]. 
Taken together, all these observations witness for non-occasional link(s) between on-
cocytomas/oncocytoid metaplasia of epithelial cells and autoimmunity. 
The cryoablation procedure is an approach used to cure oncocytoma, commonly for 
benign conditions such as cryoablation after a congelation biopsy with a low risk of com-
plications [38]. However, complications are linked with this procedure, such as ureteral 
obstruction months after the surgery [39].
In conclusion, the present case brings other neoplasia associated with RA/SS pa-
tients, to our knowledge never described in literature before. Physicians should be alert 
to an incidental mass found in abdominal imaging studies in their patients. Nevertheless, 
oncocytic metaplasia, dysplasia and oncocytomas are related to several autoimmune dis-
orders, and in our patient their comorbidity is, most probably, non-coincidental, because 
they have common links of pathogenesis. 
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